Other Clinical Trial - Special Drug Use Surveillance of Irribow in Female

Updated 06/21/2024

Status Completed

Clinical Trial Summary

The purpose of the survey is to evaluate the safety and efficacy of Irribow and Irribow OD Tablets in post-marketing medical practice and to examine the status of treatment compliance.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Diarrhea
Diarrhea-predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome

Clinical Trial Details

NCT number	NCT02612649
Study type	Observational
Source	Astellas Pharma Inc
Contact
Status	Completed
Phase
Start date	October 1, 2015
Completion date	March 31, 2018

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT04095988` - Allogeneic Microbiota-reconstitution (AMR) in Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)	N/A
	Completed	`NCT01736423` - A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome	Phase 3
	Completed	`NCT01414244` - Glutamine for the Treatment of Patients With Irritable Bowel Syndrome	Phase 2
	Completed	`NCT03977155` - Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)	Phase 2
	Completed	`NCT02163213` - Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D	N/A
	Terminated	`NCT01358708` - Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg	Phase 3
	Not yet recruiting	`NCT06346847` - Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS	N/A
	Not yet recruiting	`NCT05687435` - Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)	Phase 2/Phase 3
	Completed	`NCT01870895` - A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)	Phase 3
	Recruiting	`NCT05593367` - Effects of Vitamin D on Gut Microbiota, Intestinal Barrier in IBS-D Patients
	Completed	`NCT02538692` - Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome	Phase 2/Phase 3
	Completed	`NCT03099785` - Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D	Phase 2
	Recruiting	`NCT05369884` - Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D	Early Phase 1
	Completed	`NCT01350570` - Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial	Phase 2/Phase 3